Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

Objective: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. Th...

Full description

Bibliographic Details
Main Authors: Ila M. Linares, Antonio W. Zuardi, Luis C. Pereira, Regina H. Queiroz, Raphael Mechoulam, Francisco S. Guimarães, José A. Crippa
Format: Article
Language:English
Published: Associação Brasileira de Psiquiatria (ABP) 2018-10-01
Series:Brazilian Journal of Psychiatry
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462018005007102&lng=en&tlng=en
_version_ 1818527814953992192
author Ila M. Linares
Antonio W. Zuardi
Luis C. Pereira
Regina H. Queiroz
Raphael Mechoulam
Francisco S. Guimarães
José A. Crippa
author_facet Ila M. Linares
Antonio W. Zuardi
Luis C. Pereira
Regina H. Queiroz
Raphael Mechoulam
Francisco S. Guimarães
José A. Crippa
author_sort Ila M. Linares
collection DOAJ
description Objective: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method. Method: A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points. Results: Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. Conclusion: Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice.
first_indexed 2024-12-11T06:41:15Z
format Article
id doaj.art-1ad2c858743c480d9331e07ce8ac05fc
institution Directory Open Access Journal
issn 1809-452X
language English
last_indexed 2024-12-11T06:41:15Z
publishDate 2018-10-01
publisher Associação Brasileira de Psiquiatria (ABP)
record_format Article
series Brazilian Journal of Psychiatry
spelling doaj.art-1ad2c858743c480d9331e07ce8ac05fc2022-12-22T01:17:13ZengAssociação Brasileira de Psiquiatria (ABP)Brazilian Journal of Psychiatry1809-452X2018-10-01010.1590/1516-4446-2017-0015S1516-44462018005007102Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking testIla M. LinaresAntonio W. ZuardiLuis C. PereiraRegina H. QueirozRaphael MechoulamFrancisco S. GuimarãesJosé A. CrippaObjective: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method. Method: A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points. Results: Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. Conclusion: Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462018005007102&lng=en&tlng=enAnxietycannabiscannabidiolCBDsimulated public speaking
spellingShingle Ila M. Linares
Antonio W. Zuardi
Luis C. Pereira
Regina H. Queiroz
Raphael Mechoulam
Francisco S. Guimarães
José A. Crippa
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Brazilian Journal of Psychiatry
Anxiety
cannabis
cannabidiol
CBD
simulated public speaking
title Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_full Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_fullStr Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_full_unstemmed Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_short Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
title_sort cannabidiol presents an inverted u shaped dose response curve in a simulated public speaking test
topic Anxiety
cannabis
cannabidiol
CBD
simulated public speaking
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462018005007102&lng=en&tlng=en
work_keys_str_mv AT ilamlinares cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT antoniowzuardi cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT luiscpereira cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT reginahqueiroz cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT raphaelmechoulam cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT franciscosguimaraes cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest
AT joseacrippa cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest